EW
SMMT icon

Evoke Wealth’s Summit Therapeutics SMMT Stock Holding History

Evoke Wealth’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$190K Hold
10,000
– – ﹤0.01% 678
2025
Q4 		$175K Hold
10,000
– – ﹤0.01% 647
2025
Q3 		$207K Hold
10,000
– – ﹤0.01% 603
2025
Q2 		$213K Buy
+10,000
New +$228K ﹤0.01% 551

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Evoke Wealth's SMMT Position: Q1 2026 in Review

Evoke Wealth reduced its Summit Therapeutics (SMMT) stake by 3.5% in Q1 2026, selling an estimated $6.21K and leaving 10,668 shares worth $202K. The position accounts for ﹤0.01% of the portfolio, ranked #671.

Evoke Wealth first reported a position in SMMT in Q2 2021 and has held it in 13 quarters since. The position peaked at $329K in Q3 2024. 222 funds tracked by Wall St. Rank hold SMMT as of Q1 2026.

  • Evoke Wealth held 10,668 shares of Summit Therapeutics worth $202K as of Q1 2026.
  • Evoke Wealth sold 384 Summit Therapeutics shares in Q1 2026, an estimated $6.21K.
  • Summit Therapeutics made up ﹤0.01% of Evoke Wealth's portfolio in Q1 2026, its #671 holding.
  • Evoke Wealth first reported a position in Summit Therapeutics in Q2 2021 and has held it in 13 quarters since.
  • Evoke Wealth's Summit Therapeutics position peaked at $329K in Q3 2024.
  • 222 funds tracked by Wall St. Rank held Summit Therapeutics as of Q1 2026.

Based on Evoke Wealth's 13F filing for Q1 2026, filed 15 May 2026.